An Australian researcher has contributed to a new study demonstrating that lower carbohydrate consumption can potentially put type 2 diabetes into remission. Read more

An Australian researcher has contributed to a new study demonstrating that lower carbohydrate consumption can potentially put type 2 diabetes into remission. Read more
Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) after it produced a similar effect to Eylea in twin clinical trials, but with half the dosing regimen in several patients. Read more
Despite vehement opposition from ophthalmologists, the MBS Taskforce has forged ahead with plans to cut the rebate for intravitreal injections and consider allowing nurses and optometrists to perform the procedure in its final report to the Federal Government. Read more
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to treat diabetic macular edema (DME). Read more
Retina Australia has awarded a total of $160,000 in study grants to some of the biggest names in Australian retinal research. Read more
Professor Robyn Guymer has led an expert panel to update RANZCO’s Referral Pathway for Age-Related Macular Degeneration (AMD) Management, which accounts for greater accessibility to retinal imaging equipment and reminds clinicians to be aware of nearby clinical trials. Read more
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ahead of pivotal Phase 3 trials of its lead drug candidate. Read more
Australian of the Year and ophthalmologist Dr James Muecke has endorsed a new campaign aimed at motivating Australians in their 50s to have a macula check after it was revealed most in this age group are unable to identify macular disease risk factors. Read more
Australian researchers are using genetic testing to identify as many people as possible with inherited retinal disease (IRD), in preparation for an influx of life-changing gene and stem cell therapies expected over the next decade. Read more
For 40 years laser therapy has been the standard treatment for proliferative diabetic retinopathy (PDR), but now Australian ophthalmologists have a new option following regulatory approval of an existing drug. Read more